Arbutus Biopharma is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.
Arbutus Biopharma is a publicly traded company on using the ticker symbol ABUS.
Detailed information on company financials and operating reports can be found here:
: ABUS
Note: Arbutus Biopharma's revenues are gauged from an analysis of company filings.
Investor Activity
Arbutus Biopharma has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
December 30, 2021
1
100%
$15 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Arbutus Biopharma is developing and marketing.
Arbutus Biopharma doesn't have any recent trademark applications, indicating Arbutus Biopharma is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
ARBUTUS Pharmaceutical preparations for the treatment of hepatitis
01/07/2024
See all trademarks and details in the Full Report.
Market Share of Arbutus Biopharma's Largest Competitors
A competitive analysis shows these companies are in the same general field as Arbutus Biopharma, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Arbutus Biopharma.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Arbutus Biopharma and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.